These Companies are Changing Biotech & Biopharma with AI in 2024

<p>This Hong Kong-based company used its AI platform, Pharma.AI, to design a novel drug candidate for idiopathic pulmonary fibrosis (IPF) in 18 months. The candidate, ISM001, has shown promising results in preclinical studies and is now entering Phase I clinical trials. This is a timeline previously unheard of in traditional drug development processes. The candidate has already demonstrated promising results in preclinical studies, which is an encouraging sign of its potential effectiveness. This rapid progression from concept to clinical trials underscores the transformative impact of AI in accelerating drug discovery and bringing new treatments to the market more swiftly and efficiently.</p> <p><a href="https://odsc.medium.com/these-companies-are-changing-biotech-biopharma-with-ai-in-2024-e47323946e94"><strong>Read More</strong></a></p>